LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Listă Acțiuni・Aclaris Therapeutics Inc

Search

Aclaris Therapeutics Inc

Închisă

4.51 -6.24

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

4.48

Maxim

4.8100000000000005

Indicatori cheie
By Trading Economics
Venit	-29K -20M
Vânzări	701K 2M
EPS	-0.15
Marjă de profit	-993.186
Angajați	69
EBITDA	-2.5M -22M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+103.93% upside

Dividende
By Dow Jones
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	59M 691M
Deschiderea anterioară	10.75
Închiderea anterioară	4.51

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

1.28 / 1.33 Suport & Rezistență

Aclaris Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 mai 2026, 22:47 UTC

Acțiuni populare

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mai 2026, 22:16 UTC

Achiziții, Fuziuni, Preluări

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mai 2026, 22:00 UTC

Principalele dinamici ale pieței

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mai 2026, 18:09 UTC

Principalele dinamici ale pieței

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 mai 2026, 16:02 UTC

Câștiguri

Principalele dinamici ale pieței

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 mai 2026, 14:55 UTC

Principalele dinamici ale pieței

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 mai 2026, 14:43 UTC

Principalele dinamici ale pieței

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 mai 2026, 22:17 UTC

Achiziții, Fuziuni, Preluări

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:59 UTC

Achiziții, Fuziuni, Preluări

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mai 2026, 21:50 UTC

Achiziții, Fuziuni, Preluări

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 20:19 UTC

Acțiuni populare

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mai 2026, 19:41 UTC

Achiziții, Fuziuni, Preluări

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mai 2026, 18:35 UTC

Câștiguri

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 mai 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 mai 2026, 16:50 UTC

Achiziții, Fuziuni, Preluări

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 mai 2026, 16:24 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15 mai 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 mai 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 mai 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15 mai 2026, 15:20 UTC

Câștiguri

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 mai 2026, 14:33 UTC

Market Talk

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Comparație

Modificare preț

Aclaris Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

103.93% sus

Prognoză pe 12 luni

Medie 10.38 USD 103.93%

Maxim 16 USD

Minim 4 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAclaris Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

7

Cumpărare

1

Păstrare

0

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Aclaris Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

1.28 / 1.33Suport & Rezistență

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

All events are bearish.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Alte acțiuni din sector

LLY

Eli Lilly and Co.

1,004

JNJ

Johnson and Johnson

226.76

ABBV

AbbVie Inc

210.42

UNH

UnitedHealth Group Inc

393.66

AZN

AstraZeneca PLC

181.62

Live chat